Clinical data of patients with T2D on sitagliptin-persistent treatment, at baseline, after 12 months, and after 48 months of follow–up
| Mean value | 95% CI | Median value | SD | Shapiro-Wilk significance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||||||||
| M (N=106) | F (N=64) | M (N=106) | F (N=64) | M (N=106) | F (N=64) | M (N=106) | F (N=64) | M (N=106) | F (N=64) | M (N=106) | F (N=64) | |
| Age (years) | 63.60 | 65.61 | 61.91 | 63.62 | 65.30 | 67.60 | 64.50 | 66.00 | 8.80 | 7.95 | 0.469 | 0.742 |
| T2D duration (years) | 11.58 | 13.58 | 10.17 | 11.60 | 13.00 | 15.55 | 10.00 | 13.50 | 7.33 | 7.90 | 0.000 | 0.000 |
| BMI at baseline | 29.88 | 30.47 | 28.94 | 29.16 | 30.81 | 31.77 | 29.25 | 29.80 | 4.86 | 5.24 | 0.000 | 0.015 |
| FPG at baseline | 172.98 | 165.78 | 165.78 | 157.21 | 180.18 | 174.36 | 168.00 | 169.00 | 37.37 | 34.33 | 0.230 | 0.015 |
| HbA1c (%) at baseline | 8.37 | 8.22 | 8.21 | 8.07 | 8.54 | 8.38 | 8.40 | 8.20 | 0.87 | 0.63 | 0.234 | 0.112 |
| HbA1c (%) after 12 months | 7.31 | 7.41 | 7.14 | 7.24 | 7.49 | 7.59 | 7.30 | 7.50 | 0.91 | 0.69 | 0.000 | 0.205 |
| HbA1c (%) after 48 months | 7.33 | 7.32 | 7.19 | 7.15 | 7.48 | 7.48 | 7.40 | 7.20 | 0.75 | 0.65 | 0.319 | 0.215 |
| UKPDS (log10) at baseline | 1.36 | 1.14 | 1.31 | 1.08 | 1.40 | 1.20 | 1.38 | 1.15 | 0.24 | 0.23 | 0.250 | 0.425 |
| UKPDS (log10) after 12 months | 1.30 | 1.12 | 1.25 | 1.05 | 1.35 | 1.18 | 1.32 | 1.15 | 0.25 | 0.25 | 0.082 | 0.317 |
| UKPDS (log10) after 48 months | 1.33 | 1.12 | 1.28 | 1.07 | 1.38 | 1.18 | 1.35 | 1.13 | 0.25 | 0.23 | 0.194 | 0.843 |
BMI, body mass index; F, females; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; M, males; T2D, type 2 diabetes; UKPDS, the UK Prospective Diabetes Study.